All In MedTech

Device Trial Radar · NCT07035288

PulseSelect Based Pulmonary Vein Isolation and Ablation in Patients With Atrial Fibrillation

Electroanatomical Mapping Versus Fluoroscopy Based Pulmonary Vein Isolation by Means of PulseSelect Catheter in Patients With Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 1, 2024

Primary completion

Jun 30, 2025

Study completion Jul 10, 2025

Sponsor

Lead sponsor
Tsiachris DimitriosAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic Atrial Fibrillation Solutions
First posted
Jun 25, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Electroanatomical mapping (EAM) based pulmonary vein isolation (PVI) by means of PulseSelect catheter and deep sedation will be compared to fluoroscopy based pulmonary vein isolation in patients with atrial fibrillation in the acute and long term (2 months remapping).

Conditions

  • Atrial Fibrillation (AF)
  • Catheter Ablation
  • Pulmonary Vein Isolation

Interventions

  • EAM based Pulmonary Vein IsolationDevice

    20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to EAM by means of the PulseSelect catheter. Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed

  • Fluoro based pulmonary vein ablationDevice

    20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to Fluoroscopy by means of the PulseSelect catheter. Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durability of PVITime frame: 2 to 3 months post index ablation
  2. PVI durability by means of a fluoroscopy-based or an EAM-based index procedureTime frame: 2 to 3 months post index ablation
  3. Identification of pulmonary vein isolation gaps acutely based on EAMTime frame: 2 to 3 months post index ablation

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital

    Athens, Attica, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.